ALDX MEXC RealStocks
Own real ALDX shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-13 21:57:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Aldeyra Therapeutics, Inc. (ALDX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.65, with a market capitalization of $38.03M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.53 to $5.93. This page covers its latest market performance, valuation, price trends and company information.
$38.03M | |
$0.61 | |
$0.68 | |
$0.59 | |
$0.63 | |
694.47K | |
1.14M | |
-- | |
$5.93 | |
$0.53 | |
-- | |
-- |
Aldeyra Therapeutics, Inc. (ALDX) is trading at $0.68 in after-hours trading as of 2026-11-13 21:51:00, up 5.39% ($0.04) from the regular-session close of $0.65.
After-hours trading shows how investors are pricing ALDX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Aldeyra Therapeutics, Inc. (ALDX) moved from $0.62 to $0.65, representing a gain of 5.37% ($0.03).
The stock traded between $0.57 and $0.70 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 635.70 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 2.3%
ALDX is currently trading at $0.65, placing it 2.3% of the way from its 52-week low of $0.53 to its 52-week high of $5.93. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 6 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Aldeyra Therapeutics, Inc. (ALDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to ALDX, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between ALDX shares and USD.
ALDX Shares to USD
1.00 ALDX shares = 0.649 USD
Calculations are estimates based on the latest available price and are for reference only.